News for Apellis Pharma Stock (APLS)

Apellis Crashes As Safety Issues Outweigh Massive Eye-Drug Sales Beat

Investors Business Daily • 07/31/23

Apellis Pharmaceuticals, Inc. (APLS) Q2 2023 Earnings Call Transcript

Seeking Alpha • 07/31/23

Apellis Investigation Notification: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors

PRNewsWire • 07/31/23

Apellis Pharmaceuticals Reports Second Quarter 2023 Financial Results

GlobeNewsWire • 07/31/23

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 07/31/23

SYFOVRE® (pegcetacoplan injection) Continued to Demonstrate Increasing Treatment Effects Over 30 Months in Patients with Geographic Atrophy (GA)

GlobeNewsWire • 07/30/23

Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy

GlobeNewsWire • 07/29/23

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

Accesswire • 07/29/23

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire • 07/28/23

APLS LOSS ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - APLS

PRNewsWire • 07/27/23

SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire • 07/27/23

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 07/25/23

Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results

GlobeNewsWire • 07/24/23

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire • 07/24/23

APLS Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) Investors

Business Wire • 07/21/23

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire • 07/21/23

Apellis (APLS) Plunges on Safety Issues With Eye Treatment

Zacks Investment Research • 07/19/23

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Apellis Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation – APLS

Business Wire • 07/18/23

Down -41.23% in 4 Weeks, Here's Why Apellis Pharmaceuticals, Inc. (APLS) Looks Ripe for a Turnaround

Zacks Investment Research • 07/18/23

Apellis: Exercise Caution In Response To Safety Signal (Rating Downgrade)

Seeking Alpha • 07/18/23

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Apellis Pharmaceuticals, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire • 07/18/23

Apellis (APLS) Stock Surges 62% in 6 Months: Here's Why

Zacks Investment Research • 07/17/23

Apellis Pharma Crashes After Safety Report Undercuts Its Newest Eye Drug

Investors Business Daily • 07/17/23

Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

GlobeNewsWire • 07/10/23

Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference

GlobeNewsWire • 06/07/23